RNS Number : 9955K

Arix Bioscience Plc

12 May 2022

12 May 2022


Electronic Communication with Shareholders

The Company is pleased to announce it has today posted a letter to all Shareholders (the "Letter") requesting their individual consent to the use of electronic means of communication and in that regard choose from three options.

The Letter is also available on the Company's website:



   Email:     ir@arixbioscience.com 
   LEI:          213800OVT3AHQCXNIX43 
   Registrar and Receiving Agent:   Equiniti Limited - 0371 384 2030 or +44 121 415 7047 

Company Secretary: Kin Company Secretarial Limited - +44 20 8819 6486

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.



(END) Dow Jones Newswires

May 12, 2022 04:00 ET (08:00 GMT)

Arix Bioscience (LSE:ARIX)
Historical Stock Chart
From May 2022 to Jun 2022 Click Here for more Arix Bioscience Charts.
Arix Bioscience (LSE:ARIX)
Historical Stock Chart
From Jun 2021 to Jun 2022 Click Here for more Arix Bioscience Charts.